290 related articles for article (PubMed ID: 15138582)
1. Stimulation of cells from a non-invaded and an invaded lymph node with a HER-2+ tumor with peptides corresponding to T-cell epitopes E75 and G89 induced expansion of central memory cells (TCM) from the metastasis-negative lymph nodes.
Ko BK; Efferson CL; Kawano K; Kuerer HM; Sahin A; Murray JL; Ioannides CG
Int J Oncol; 2004 Jun; 24(6):1413-8. PubMed ID: 15138582
[TBL] [Abstract][Full Text] [Related]
2. Helper peptide G89 (HER-2:777-789) and G89-activated cells regulate the survival of effectors induced by the CTL epitope E75 (HER-2, 369-377). Correlation with the IFN-gamma: IL-10 balance.
Lee TV; Johnston DA; Thomakos N; Honda T; Efferson CL; Ioannides CG
Anticancer Res; 2002; 22(3):1481-90. PubMed ID: 12168827
[TBL] [Abstract][Full Text] [Related]
3. HER-2 peptides p776 and F7, N-terminal-linked with Ii-Key tetramer (LRMK) help the proliferation of E75-TCR+ cells: The dependency of help on the side chains of LRMK-extended peptide pointed towards the T cell receptor.
Li Y; Ishiyama S; Matsueda S; Tsuda N; Ioannides CG
Oncol Rep; 2008 Jun; 19(6):1445-52. PubMed ID: 18497949
[TBL] [Abstract][Full Text] [Related]
4. Stimulation of human T cells by an influenza A vector expressing a CTL epitope from the HER-2/neu protooncogene results in higher numbers of antigen-specific TCRhi cells than stimulation with peptide. Divergent roles of IL-2 and IL-15.
Efferson CL; Kawano K; Tsuda N; Palese P; García-Sastre A; Ioannides CG
Anticancer Res; 2005; 25(2A):715-24. PubMed ID: 15868901
[TBL] [Abstract][Full Text] [Related]
5. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.
Mortarini R; Piris A; Maurichi A; Molla A; Bersani I; Bono A; Bartoli C; Santinami M; Lombardo C; Ravagnani F; Cascinelli N; Parmiani G; Anichini A
Cancer Res; 2003 May; 63(10):2535-45. PubMed ID: 12750277
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity of undifferentiated, high-TCR density CD8+ cells to methylene groups appended to tumor antigen determines their differentiation or death.
Kawano K; Efferson CL; Peoples GE; Carter D; Tsuda N; Murray JL; Ioannides CG
Cancer Res; 2005 Apr; 65(7):2930-7. PubMed ID: 15805296
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial.
Mittendorf EA; Storrer CE; Foley RJ; Harris K; Jama Y; Shriver CD; Ponniah S; Peoples GE
Cancer; 2006 Jun; 106(11):2309-17. PubMed ID: 16596621
[TBL] [Abstract][Full Text] [Related]
8. Human papillomavirus 16 E6-specific CD45RA+ CCR7+ high avidity CD8+ T cells fail to control tumor growth despite interferon-gamma production in patients with cervical cancer.
Zehbe I; Kaufmann AM; Schmidt M; Hohn H; Maeurer MJ
J Immunother; 2007; 30(5):523-32. PubMed ID: 17589293
[TBL] [Abstract][Full Text] [Related]
9. IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL.
Dubsky P; Saito H; Leogier M; Dantin C; Connolly JE; Banchereau J; Palucka AK
Eur J Immunol; 2007 Jun; 37(6):1678-90. PubMed ID: 17492620
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous production of T helper-1-like cytokines and cytolytic activity by tumor-specific T cells in ovarian and breast cancer.
Goedegebuure PS; Douville CC; Doherty JM; Linehan DC; Lee KY; Ganguly EK; Eberlein TJ
Cell Immunol; 1997 Feb; 175(2):150-6. PubMed ID: 9023420
[TBL] [Abstract][Full Text] [Related]
11. Induction of tumor-reactive CTL by C-side chain variants of the CTL epitope HER-2/neu protooncogene (369-377) selected by molecular modeling of the peptide: HLA-A2 complex.
Castilleja A; Carter D; Efferson CL; Ward NE; Kawano K; Fisk B; Kudelka AP; Gershenson DM; Murray JL; O'Brian CA; Ioannides CG
J Immunol; 2002 Oct; 169(7):3545-54. PubMed ID: 12244144
[TBL] [Abstract][Full Text] [Related]
12. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer.
Murray JL; Gillogly ME; Przepiorka D; Brewer H; Ibrahim NK; Booser DJ; Hortobagyi GN; Kudelka AP; Grabstein KH; Cheever MA; Ioannides CG
Clin Cancer Res; 2002 Nov; 8(11):3407-18. PubMed ID: 12429628
[TBL] [Abstract][Full Text] [Related]
13. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
[TBL] [Abstract][Full Text] [Related]
14. Proliferative and cytokine responses to class II HER-2/neu-associated peptides in breast cancer patients.
Tuttle TM; Anderson BW; Thompson WE; Lee JE; Sahin A; Smith TL; Grabstein KH; Wharton JT; Ioannides CG; Murray JL
Clin Cancer Res; 1998 Aug; 4(8):2015-24. PubMed ID: 9717833
[TBL] [Abstract][Full Text] [Related]
15. Differentiation of CD8+ T cells from tumor-invaded and tumor-free lymph nodes of melanoma patients: role of common gamma-chain cytokines.
Anichini A; Scarito A; Molla A; Parmiani G; Mortarini R
J Immunol; 2003 Aug; 171(4):2134-41. PubMed ID: 12902520
[TBL] [Abstract][Full Text] [Related]
16. Human breast carcinoma patients develop clonable oncofetal antigen-specific effector and regulatory T lymphocytes.
Rohrer JW; Barsoum AL; Dyess DL; Tucker JA; Coggin JH
J Immunol; 1999 Jun; 162(11):6880-92. PubMed ID: 10352310
[TBL] [Abstract][Full Text] [Related]
17. Identification of activated tumor antigen-reactive CD8+ cells in healthy individuals.
Lee TV; Anderson BW; Peoples GE; Castilleja A; Murray JL; Gershenson DM; Ioannides CG
Oncol Rep; 2000; 7(3):455-66. PubMed ID: 10767352
[TBL] [Abstract][Full Text] [Related]
18. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients.
Peoples GE; Gurney JM; Hueman MT; Woll MM; Ryan GB; Storrer CE; Fisher C; Shriver CD; Ioannides CG; Ponniah S
J Clin Oncol; 2005 Oct; 23(30):7536-45. PubMed ID: 16157940
[TBL] [Abstract][Full Text] [Related]
19. Distribution and functional analysis of memory antiviral CD8 T cell responses in HIV-1 and cytomegalovirus infections.
Ellefsen K; Harari A; Champagne P; Bart PA; Sékaly RP; Pantaleo G
Eur J Immunol; 2002 Dec; 32(12):3756-64. PubMed ID: 12516570
[TBL] [Abstract][Full Text] [Related]
20. N-terminally LRMK-linked HER-2 peptides, AE-37 [p776(774-788)] and AE-47 [Ava-F7(776-788)], aid differentiation of E75-TCR+CD8+ cells to perforin-positive cells.
Matsueda S; Gao H; Efferson CL; Tsuda N; Ishiyama S; Li Y; Ioannides MG; Fisk B; Peoples GE; Ioannides CG
Anticancer Res; 2009 Jul; 29(7):2427-35. PubMed ID: 19596910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
